

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
20737771 322	Immunoglobulin M (100 tests)	System-ID 07 3777 1 COBAS INTEGRA 400 plus COBAS INTEGRA 800
20737267 322	Serumproteins T Standard (5 × 0.5 mL)	System-ID 07 3726 7
10557897 122	Precinorm Protein (3 × 1 mL)	System-ID 07 9105 9
10557897 160	Precinorm Protein (3 × 1 mL, for USA)	System-ID 07 9105 9
10171743 122	Precinorm U (20 × 5 mL)	System-ID 07 7997 0
10171735 122	Precinorm U (4 × 5 mL)	System-ID 07 7997 0
11333127 122	Precipath Protein (3 × 1 mL)	System-ID 07 9106 7
11333127 160	Precipath Protein (3 × 1 mL, for USA)	System-ID 07 9106 7
03121291 122	Precipath PUC (4 × 3 mL)	System-ID 07 6757 3
05117003 190	PreciControl ClinChem Multi 1 (20 × 5 mL)	System-ID 07 7469 3
05947626 190	PreciControl ClinChem Multi 1 (4 × 5 mL)	System-ID 07 7469 3
05947626 160	PreciControl ClinChem Multi 1 (4 × 5 mL, for USA)	System-ID 07 7469 3
05117216 190	PreciControl ClinChem Multi 2 (20 × 5 mL)	System-ID 07 7470 7
05947774 190	PreciControl ClinChem Multi 2 (4 × 5 mL)	System-ID 07 7470 7
05947774 160	PreciControl ClinChem Multi 2 (4 × 5 mL, for USA)	System-ID 07 7470 7
20756350 322	NaCl Diluent 9 % (6 × 22 mL)	System-ID 07 5635 0
20721867 322	Accelerator I (100 mL)	System-ID 07 2186 7

English

System information

Test IGM, test ID 0-077 (standard application)

Test IGMP, test ID 0-177 (sensitive application)

Intended use

In vitro test for the quantitative immunological determination of human immunoglobulin M in serum and plasma on COBAS INTEGRA systems.

In addition to the standard application (test IGM, test ID 0-077), the sensitive application (test IGMP, test ID 0-177) is designed for the quantitative determination of low IgM concentrations in e.g. pediatric samples.

Summary^{1,2}

Immunoglobulins protect the human body against invading organisms and agents. Immunoglobulins contain an antigen binding part (Fab portion) and a Fc portion of which the latter can interact with cells of the immune system and the complement factors. The immunoglobulin Fab part recognizes antigens in solution (e.g. toxins) and antigens associated with microorganisms (e.g. bacteria, viruses). The antigen binding site may initiate the direct neutralization of toxins, the sensitization of immunocompetent cells, the reduction of viral infectivity, or the development of an inflammatory reaction.

As a normal result of infections all immunoglobulin classes increase in serum. Raised IgM levels are found during liver cell diseases, (e.g. hepatitis, liver cirrhosis), autoimmune diseases, and especially during acute and chronic viral infections. Malignant cell proliferation of an immunoglobulin producing cell (plasma cell) causes a serum level increase of a single immunoglobulin (plasmacytoma). Immunoglobulin deficiencies may be due to protein loss syndromes, inherited deficiencies, or may be secondary to lymphoid malignancies. Due to the slow onset of IgM synthesis, the IgM concentration in serum of infants is lower than in adults.

It is known that the so-called paraproteins secreted in monoclonal gammopathies (monoclonal immunoglobulinemia) may differ from the respective immunoglobulins of polyclonal origin by amino acid composition and size. This may impair the binding to the antibody, and hence impair accurate quantitation.

Test principle³

Immunoturbidimetric assay

Human IgM forms a precipitate with a specific antiserum which is determined turbidimetrically at 340 nm.

Reagents - working solutions

R1 Anti-IgM T antiserum (rabbit) specific for human IgM in phosphate buffer, stabilizers

SR Reagent for antigen excess check
IgM in diluted serum (human), stabilizers

R1 is in position B and SR is in position C.

Precautions and warnings

Pay attention to all precautions and warnings listed in Section 1 / Introduction of this Method Manual.

All human material should be considered potentially infectious. All products derived from human blood are prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV.

The testing methods applied were FDA-approved or cleared in compliance with the European Directive 98/79/EC, Annex II, List A. However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.^{4,5}

For USA: For prescription use only.

Reagent handling

Ready for use

Storage and stability

Shelf life at 2-8 °C See expiration date on **cobas c** pack label

COBAS INTEGRA 400 plus system

On-board in use at 10-15 °C 12 weeks

COBAS INTEGRA 800 system

On-board in use at 8 °C 12 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable:

Serum

Plasma: Li-heparin plasma

Immunoglobulin M

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Samples and controls are automatically prediluted with NaCl solution by the instrument.

Centrifuge samples containing precipitates before performing the assay.

Stability: ⁶	2 months at 15-25 °C
	4 months at 2-8 °C
	6 months at (-15)-(-20) °C

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

1. **IGM, IGMP**
NaCl Diluent 9 %, Cat. No. 20756350 322, system-ID 07 5635 0 for automatic sample dilution and standard serial dilutions.
NaCl Diluent 9 % is stable for 4 weeks on-board
COBAS INTEGRA 400 plus/800 analyzers.
2. **IGMP**
Accelerator I as special diluent (SD).
Stability on-board in use: 7 days.

Both auxiliary reagents are placed in their predefined rack position.

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Applications for serum and plasma

COBAS INTEGRA 400 plus test definition

Measuring mode	Absorbance
Abs. calculation mode	Endpoint
Reaction direction	Increase
Reaction start with	Sample
Antigen excess check	Yes (with SR)
Unit	g/L

Standard application (IGM)

Reaction mode	D-R1-S-SR
Wavelength A	340 nm
Calc. first/last	T ₀ /33
Typical prozone effect	> 58 g/L (> 59.7 µmol/L or > 5800 mg/dL)
Predilution factor	21

Sensitive application (IGMP)

Reaction mode	D-R1-SD/S-SR
Wavelength A/B	340/659 nm
Calc. first/last	T ₀ /33
Typical prozone effect	> 22 g/L (> 22.7 µmol/L or > 2200 mg/dL)
Predilution factor	11

Pipetting parameters

Standard application (IGM)		Diluent (H ₂ O)
R1	65 µL	20 µL

Sample	13 µL	20 µL
SR	13 µL	
Total volume	131 µL	
<i>Sensitive application (IGMP)</i>		Diluent (H ₂ O)
R1	65 µL	10 µL
Sample	26 µL	
Special diluent (SD)	20 µL	
SR	16 µL	
Total volume	137 µL	

COBAS INTEGRA 800 test definition

Measuring mode	Absorbance
Abs. calculation mode	Endpoint
Reaction direction	Increase
Reaction start with	Sample
Antigen excess check	Yes (with SR)
Unit	g/L

Standard application (IGM)

Reaction mode	D-R1-S-SR
Wavelength A	340 nm
Calc. first/last	T ₀ /44
Typical prozone effect	> 49 g/L (> 50.5 µmol/L or > 4900 mg/dL)
Predilution factor	21

Sensitive application (IGMP)

Reaction mode	D-R1-SD/S-SR
Wavelength A/B	340/652 nm
Calc. first/last	T ₀ /44
Typical prozone effect	> 22 g/L (> 22.7 µmol/L or > 2200 mg/dL)
Predilution factor	11

Pipetting parameters

Standard application (IGM)		Diluent (H ₂ O)
R1	65 µL	20 µL
Sample	13 µL	20 µL
SR	13 µL	
Total volume	131 µL	

Sensitive application (IGMP)

R1	65 µL	Diluent (H ₂ O) 10 µL
Sample	26 µL	
Special diluent (SD)	20 µL	
SR	16 µL	
Total volume	137 µL	

Note

The sensitive application (IGMP) is designed for IgM determination in samples with low IgM concentrations (e.g. pediatric specimens).

Calibration

Calibrator	Serumproteins T Standard
------------	--------------------------

Calibration dilution ratio	<i>Standard application (IGM)</i> 1:3, 1:6, 1:12, 1:24, 1:48, 1:96 performed automatically by the instrument <i>Sensitive application (IGMP)</i> 1:6, 1:12, 1:24, 1:48, 1:96, 1:192 performed automatically by the instrument
Calibration mode	Logit/log 5
Calibration replicate	Duplicate recommended
Calibration interval	Each lot and as required following quality control procedures

Enter the assigned lot-specific IgM value of the undiluted calibrator, indicated in the package insert of the Serumproteins T Standard.

Traceability: This method has been standardized with regard to the IFCC/BCR/CAP reference preparation CRM 470 (RPPHS 91/0619) for 14 serum proteins.⁷

Quality control

Standard application (IGM)

Control low IGM	Precinorm Protein, Precinorm U, or PreciControl ClinChem Multi 1
Control high IGM	Precipath Protein or PreciControl ClinChem Multi 2

Sensitive application (IGMP)

Control low IGMP	Precipath PUC
Control high IGMP	Precinorm Protein or PreciControl ClinChem Multi 1
Control interval	24 hours recommended
Control sequence	User defined
Control after calibration	Recommended

For quality control, use control materials as listed in the "Order information" section. In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

COBAS INTEGRA analyzers automatically calculate the analyte concentration of each sample. For more details, please refer to Data Analysis in the Online Help (COBAS INTEGRA 400 plus/800 analyzers).

Conversion factors:	$\text{g/L} \times 1.03 = \mu\text{mol/L}$ $\text{g/L} \times 100 = \text{mg/dL}$
---------------------	--

Molecular weight:	970000
-------------------	--------

Limitations - interference

Criterion: Recovery within $\pm 10\%$ of initial value.

Serum/plasma

Icterus:⁸ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 $\mu\text{mol/L}$ or 60 mg/dL).

Hemolysis:⁸ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 $\mu\text{mol/L}$ or 1000 mg/dL).

Lipemia (Intralipid):⁸

Standard application (IGM): No significant interference up to an L index of 150.

Sensitive application (IGMP): No significant interference up to an L index of 100.

There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors: RF-positive specimens increase the apparent IgM concentration significantly, because the most frequent isotype of rheumatoid factors is IgM-RF.

Drugs: Therapeutic drug interference was tested according to the recommendations of the VDGH⁹. No interferences were found.

As with other turbidimetric or nephelometric procedures, this test may not provide accurate results in patients with monoclonal gammopathy, due to individual sample characteristics, which can be assessed by electrophoresis.⁹

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

a) Verband der Diagnostica und Diagnostica Geräte Hersteller. Refer to section 1 / Introduction of this Method Manual for a list of drugs tested and their concentrations.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on COBAS INTEGRA analyzers. Refer to the CLEAN Method Sheet for further instructions and for the latest version of the Extra wash cycle list.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

Standard application (IGM)

0.40-5.18 g/L (0.41-5.34 $\mu\text{mol/L}$ or 40-518 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:4.7 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 4.7.

Determine samples having lower concentrations via the rerun function. For samples with lower concentrations, the rerun function reduces the sample predilution factor to 7. The results are automatically multiplied by the reduced predilution factor.

Sensitive application (IGMP)

0.05-1.26 g/L (0.05-1.30 $\mu\text{mol/L}$ or 5-126 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:3 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 3.

Determine samples having lower concentrations via the rerun function. For samples with lower concentrations, the rerun function reduces the sample predilution factor to 3.7. The results are automatically multiplied by the reduced predilution factor.

Lower limits of measurement

Standard application (IGM)

Lower detection limit of the test:

0.20 g/L (0.21 $\mu\text{mol/L}$ or 20 mg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of a zero sample (zero sample + 3 SD, repeatability, $n = 30$).

Sensitive application (IGMP)

Lower detection limit of the test:

0.05 g/L (0.05 $\mu\text{mol/L}$ or 5 mg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of a zero sample (zero sample + 3 SD, repeatability, $n = 30$).

Expected values

Adults ¹⁰	0.40-2.30 g/L (0.41-2.37 $\mu\text{mol/L}$, 40.0-230 mg/dL)
Children and juveniles ¹¹	
0-1 year	0.00-1.45 g/L (0.00-1.49 $\mu\text{mol/L}$, 0.00-145 mg/dL)
1-3 years	0.19-1.46 g/L (0.20-1.50 $\mu\text{mol/L}$, 19.0-146 mg/dL)

4-6 years	0.24-2.10 g/L (0.25-2.16 µmol/L, 24.0-210 mg/dL)
7-9 years	0.31-2.08 g/L (0.32-2.14 µmol/L, 31.0-208 mg/dL)
10-11 years	0.31-1.79 g/L (0.32-1.84 µmol/L, 31.0-179 mg/dL)
12-13 years	0.35-2.39 g/L (0.36-2.46 µmol/L, 35.0-239 mg/dL)
14-15 years	0.15-1.88 g/L (0.15-1.94 µmol/L, 15.0-188 mg/dL)
16-19 years	0.23-2.59 g/L (0.24-2.67 µmol/L, 23.0-259 mg/dL)

Roche has not evaluated reference ranges in a pediatric population.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability and intermediate precision (2 aliquots per run, 2 runs per day, 20 days). The following results were obtained:

Standard application (IGM)

	Level 1	Level 2
Mean	0.55 g/L (0.57 µmol/L or 55 mg/dL)	2.00 g/L (2.06 µmol/L or 200 mg/dL)
CV repeatability	2.4 %	1.6 %
CV intermediate precision	3.2 %	1.9 %

Sensitive application (IGMP)

	Level 1	Level 2
Mean	0.44 g/L (0.45 µmol/L or 44 mg/dL)	1.08 g/L (1.11 µmol/L or 108 mg/dL)
CV repeatability	1.9 %	1.6 %
CV intermediate precision	4.9 %	2.1 %

Method comparison

Standard application (IGM)

IgM values for human serum and plasma samples obtained on a COBAS INTEGRA 700 analyzer using the COBAS INTEGRA Immunoglobulin M reagent (sample predilution 1:21) (y) were compared with those determined using the commercially available reagents for IgM on a COBAS INTEGRA 700 analyzer (sample predilution 1:41) (x) and an alternative manufacturer's automated system (turbidimetric determination) (x). Samples were measured in duplicate. Sample size (n) represents all replicates.

		COBAS INTEGRA 700 analyzer	Alternative system
Sample size	(n)	486	556
Corr. coefficient	(r)	0.992	0.994
	(r _s)	0.984	0.992
Linear regression		y = 0.959x + 0.092 g/L	y = 1.293x - 0.341 g/L
Passing/Bablok ¹²		y = 1.000x + 0.040 g/L	y = 1.310x - 0.364 g/L

The sample concentrations were between 0.32 and 5.01 g/L (0.33-5.16 µmol/L and 32-501 mg/dL).

Sensitive application (IGMP)

IgM values for human serum and plasma samples obtained on a COBAS INTEGRA 700 analyzer using the COBAS INTEGRA Immunoglobulin M reagent (y) were compared with those determined using the commercially available reagents for IgM on a COBAS MIRA analyzer (x) and an alternative manufacturer's automated system (nephelometric

determination) (x). Samples were measured in duplicate. Sample size (n) represents all replicates.

		COBAS MIRA analyzer	Alternative system
Sample size	(n)	214	214
Corr. coefficient	(r)	0.992	0.984
	(r _s)	0.991	0.979

Linear regression y = 1.011x + 0.070 g/L y = 1.175x - 0.028 g/L

Passing/Bablok¹² y = 1.001x + 0.080 g/L y = 1.207x - 0.041 g/L

The sample concentrations were between 0.04 and 1.27 g/L (0.04-1.31 µmol/L and 4-127 mg/dL).

References

- 1 Brostoff J, Scadding GH, Male D, et al. Clinical Immunology. London: Gower Medical Publishing 1991;1:1-1.8.
- 2 Bodansky O, Latner AL. Advances in Clinical Chemistry. New York: Academic Press 1971;14:219-317.
- 3 Becker W, Rapp W, Schwick HG, et al. Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunpräzipitation. Z Klin Chem Klin Biochem. 1968;6:113-122.
- 4 Occupational Safety and Health Standards: bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- 5 Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.
- 6 Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2. Jan. 2002.
- 7 Johnson AM. A new international reference preparation for proteins in human serum. Arch Pathol Lab Med 1993;117:29-31.
- 8 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- 9 Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000;46(8 Pt 2):1230-1238.
- 10 Schumann G, Dati F. Vorläufige Referenzbereiche für 14 Proteine im Serum (für Erwachsene) nach Standardisierung immunochemischer Methoden unter Bezug auf das internationale Referenzmaterial CRM 470. Lab Med 1995;19:401-403.
- 11 Lockitch G, Halstead AC, Quigley G, et al. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem 1988;34:1618-1621. - Reference values are adapted to IFCC/BCR/CAP reference preparation CRM 470 (RPPHS 91/0619) by applying a conversion factor of 0.67.
- 12 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

CONTENT

Contents of kit



Volume after reconstitution or mixing

GTIN

Global Trade Item Number

IGM

Immunoglobulin M

cobas[®]
Specific proteins

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, COBAS INTEGRA, COBAS MIRA, PRECICONTROL, PRECINORM and PRECIPATH are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2014, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:

Roche Diagnostics, Indianapolis, IN

US Customer Technical Support 1-800-428-2336

